New Rules, New Risks

Written By Marc Townsend

How analytical labs are adapting to executive orders, the “One Big Beautiful Bill,” and rising tariffs

2025 is forcing U.S. analytical labs to rethink everything — from sourcing strategies to capital investments. 

This shift isn’t theoretical: Sweeping reciprocal tariffs are being announced daily, intensifying the pressures already created by recent executive orders and the much-hyped “One Big Beautiful Bill.” If your lab still relies on legacy procurement models, imported consumables, or capital-heavy equipment purchases, it’s time to retool your strategy. 

This summary of recent changes and how they affect labs is part of our ongoing series designed to keep you running at peak performance. Leave a comment at the end and let us know what you think!

 

What has changed in the last 2 weeks?

The White House confirmed a sharp tariff escalation:

  • The U.S. tariff rate jumps to 10 - 41% depending on the country of origin.

  • Canada, Switzerland, India, and South Africa are facing the highest rates, with that changing almost daily.

  • Only a few trading partners (UK, Japan, South Korea) received favored 15% rates.

  • According to the Yale Budget Lab, the effective U.S. tariff rate is now 18.4% — the highest since 1934 — resulting in 1.8% short-term inflation in scientific and technical sectors.

For analytical labs, this means:

  • Equipment, gases, and components sourced abroad now cost 10 – 70% more.

  • Customs delays and reclassification audits are spiking.

  • Key lab vendors like Abbott and Philips are already warning of hundreds of millions in added costs this fiscal year.

 

1. Executive orders: Compliance, sourcing & digital infrastructure

2025’s executive orders are demanding new layers of accountability from labs, especially those tied to government contracts, public health work, or biotech.

Key mandates:

  • Buy-American policies affecting consumables, service contracts, and even software licenses.

  • DEI and sustainability documentation as a requirement for federal funding and partnerships.

  • AI and data privacy controls for labs handling patient or clinical research data.

How Labs Are Adapting:

  • Restructuring supplier contracts to prioritize U.S.-based or tariff-exempt vendors.

  • Implementing carbon and diversity tracking tools in their procurement process.

  • Building AI-generated governance checklists to maintain audit-ready diagnostic workflows.

 

2. The federal budget as it stands now: New funding meets new complexity

This sweeping infrastructure and innovation package offers major upsides for labs — if they can navigate the paperwork.

What it includes:

  • Grants and tax credits for biotech, green chemistry, and advanced materials labs.

  • Reimbursements for labs installing energy-efficient equipment or switching to on-site nitrogen generation.

  • Funding for public health lab expansion and decentralized environmental monitoring.

But —

  • Qualification requires extensive documentation and often favors labs with in-house grant expertise.

  • Demand for modernized instruments has driven up lead times and capital equipment prices, even before the new tariffs hit.

How Labs Are Adapting:

  • Moving to lease-to-own models to modernize without sinking capex.

  • Partnering with CROs or regional consortiums to share infrastructure.

  • Shifting operations toward sustainable, grant-eligible upgrades.

 

3. Tariffs: The new cost driver labs can’t ignore

The new tariff wave has blindsided even well-prepared labs.

Real-world impacts:

  • Mass spectrometers, nitrogen generators, and chromatography parts sourced from the UK, China, Switzerland, or Canada are now 15 – 41% more expensive.

  • Helium and specialty gas imports face new customs coding scrutiny, adding 1–2 weeks of lead time.

  • Manufacturers are shifting costs downstream, affecting service contracts, consumables, and software subscriptions.

How Labs Are Adapting:

  • Switching from gas cylinders to on-site nitrogen generators to control supply and avoid tariffs.

  • Negotiating tariff escalation clauses in vendor contracts.

  • Increasing buffer stock of high-risk consumables and parts.

  • Reviewing HTS codes and pursuing exemptions where eligible.

 

4. Business model shifts we're seeing across the sector

Successful labs aren’t just trimming costs — they’re transforming how they operate:

Traditional Model Emerging Strategy
Buy capital equipment outright Lease or subscription model (e.g., GGS NitroLease™)
Rely on imported consumables Localize or substitute suppliers
Staff-heavy compliance tracking Automated sustainability and DEI reporting
Isolated procurement planning Cross-functional sourcing and risk modeling
 

Final Word: Adaptability is the New Compliance

Whether you're in diagnostics, food testing, pharma, or environmental chemistry, 2025's policy landscape is unforgiving to the unprepared. The labs that endure won’t be the biggest or the cheapest. They’ll be the most adaptive, strategic, and proactive.

Need to assess your lab’s exposure to tariffs and policy-driven disruptions?
We help labs lease smarter infrastructure, diversify gas sourcing, and build resilience into their supply chain.

Contact us for rational, unbiased consulting, we’re here to help.

 

References

Marc Townsend
Next

What’s next in Mass Spectrometry?